AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, and HIV. The company also provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; and Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1990 and is headquartered in Ocala, Florida.
IPO Year:
Exchange: AMEX
Website: aimimmuno.com
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Maxim Group resumed coverage of AIM ImmunoTech with a rating of Buy and set a new price target of $2.00
Fastest customizable press release news feed in the world
Video segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen's previously published antiviral research Discussion highlights Ampligen's immune-modulating mechanism, prior Biosafety Level 4 findings and potential applicability across emerging viral threats New Ebola-focused corporate presentation highlighting Ampligen's antiviral research and preparedness potential is now accessible here Access the ‘What This Means' video segment here OCALA, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the release of a Virtual Investor "What This Means" video segment featuring AIM Chie
OCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a significant milestone in its pancreatic cancer development program, with enrollment of the final subject, barring disqualifying pre-treatment circumstances. The final planned subject is scheduled for treatment in mid-June, surpassing the Company's original enrollment target of July 2026 in the Phase 2 clinical trial of AIM's drug Ampligen® (rintatolimod) combined with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care (the "DURIPANC" stud
Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola Company to release Virtual Investor "Ebola: What This Means" Segment on June 4th at 9:00 AM ET OCALA, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced it will release an on-demand video presentation detailing important previously published pre-clinical findings supporting the potential role of its lead drug Ampligen® (rin
OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company", today announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an aggregate of 7,519,351 shares of common stock, par value $0.001 per share (the "Common Stock") (or common stock equivalents in lieu thereof) at a purchase price of $0.325 per share. The gross proceeds to the Company from the offering are expected to be approximately $2.4 million, before deducting placement agent commissions and other offering expenses. In addition, in a concurrent private placement, the Company will issue and sell unregistered Series I
OCALA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a significant increase in stockholder equity and that the Company has entered into Amendment #2 to its existing promissory note agreement with Streeterville Capital, LLC, extending the maturity date to June 30, 2027. AIM recently reported stockholder equity of approximately $2.1 million as of March 31, 2026, which is a significant increase of approximately $11.9 million in stockholder equity from the reported stockholder deficit of approximately $9.8 million as of December 31, 2025. The Company has also raised equity-generating funds through various transactions since Marc
Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary Surgeon at Erasmus MC and an oncology consultant for AIM ImmunoTech, is now available on demand here OCALA, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that Professor Casper H.J. van Eijck, MD, PhD, Professor and Pancreato-biliary Surgeon at Erasmus Medical Center ("Erasmus MC") and a consultant for AIM, and AIM Chief Executive Officer Thomas K. Equels, MS, JD, participated in a Virtual Investor KOL Connect segment. The on-demand s
OCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM:AIM) ("AIM ImmunoTech" or the "Company"), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment of cancer, today announced an agreement between the Company and certain accredited investors to exercise certain outstanding Class A, Class B, Class C, Class D, Class E and Class F Warrants (the "Existing Warrants") to purchase up to an aggregate of 8,719,928 shares of common stock at a reduced exercise price of $0.48 per share for gross proceeds of approximately $4.2 million, before deducting placement agent fees and other estimated offering expenses. The Company intends t
OCALA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the Final Primary Endpoint Report on Objective Response Rate data from a University of Pittsburgh Medical Center ("UPMC") Phase 2 clinical trial – in which AIM and Merck Sharp & Dohme ("Merck") are collaborators – evaluating Ampligen® (rintatolimod) in combination with checkpoint inhibition and chemotherapy in recurrent ovarian cancer—data that may signal a major step forward in overcoming resistance to immunotherapy. The study aimed to improve clinical outcomes by overcoming the immunosuppressive tumor microenvironment characteristic of ovarian cancer through locoregional
Company to participate in Live Virtual Investor Closing Bell segment today, April 16th at 4:00 PM ET; Register for the event here OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today highlighted accelerating momentum in its pancreatic cancer program, underscored by Phase 3 trial planning underway, encouraging Phase 2 clinical signals, and a rapidly strengthening global regulatory and intellectual property ("IP") position. "The initiation of Phase 3 planning marks a critical step forward in our mission to bring Ampligen to patients with pancreatic cancer," said Thomas K. Equels, Chief Executive Officer of AIM. "With a growing body o
OCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today advised that its audited consolidated financial statements for the fiscal year ended December 31, 2025, contained an audit report from its independent registered public accounting firm with a going concern emphasis of matter. Release of this information is required by Section 610(b) of the NYSE American Company Guide, and does not represent any change or amendment to any of the Company's filings for the fiscal year ended December 31, 2025. AIM management is confident in its continued ability to raise funds based on ongoing, promising results in the development of its lead drug, Am
8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
424B5 - AIM ImmunoTech Inc. (0000946644) (Filer)
424B5 - AIM ImmunoTech Inc. (0000946644) (Filer)
8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
10-Q - AIM ImmunoTech Inc. (0000946644) (Filer)
8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
8-K - AIM ImmunoTech Inc. (0000946644) (Filer)
Live Leadership Updates
OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Company's Board of Directors (the "Board") has, by unanimous vote, appointed David Chemerow as an Independent Director to the Board, effective immediately. Mr. Chemerow brings more than 40 years of finance, accounting and operations leadership experience across multiple industries. He previously served as the Chief Financial Officer and Treasurer, and prior to that as Chief Revenue Officer, of Comscore, Inc., an American-based global media measurement and analytics company. Prior to his tenure at Comscore, Mr. Chemerow served as the Chief Operating Officer an
Believes Annual Meeting Outcome is Critical to Future of the Company and that the Current Board is Best Positioned to Continue Clinical Trial Momentum, Commercialize Ampligen and Deliver Long-Term Value for Shareholders In AIM's View, the Activist Group's Plan to Reimburse Individuals More Than $5 Million for Failed Attempts to Gain Control of the Board – Without Putting this to a Shareholder Vote – Is Grossly Irresponsible and Not in the Best Interests of All Shareholders Reminds Shareholders that Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Recommended Against Giving the Dissident Nominees Control of the AIM Board, Specifically Citing Their Lack of a Plan, Amo
Follows Announcement Earlier this Week that Ampligen Co-Founder and Former AIM CEO Agreed to Join Scientific Advisory Board if Kellner Group Nominees Are Elected Kellner Group Reiterates Plan to Revitalize AIM, Accelerate Clinical Development and Restore Value for StockholdersKellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the "Kellner Group," "we" or "us" and, as nominees, t
Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the "Kellner Group," "we" or "us" and, as nominees, the "Kellner Group Nominees") today issue the following press release in connection with their efforts to bring accountability to the entrenched, incumbent Board of Directors of AIM Immunotech Inc. (NYSE:AIM). The Kellner Group is pleased to announce that Dr. William A. Carter, M
Warns Shareholders that Activist Group's Self-Interested Agenda Could Disrupt AIM's Momentum and Destroy Chances for Near-Term Value Creation Expresses Excitement About Encouraging Progress of Clinical Trials for Ampligen in High-Value Indications Including Pancreatic Cancer Urges Shareholders to Safeguard AIM by Voting "FOR" ALL Four of the Board's Incumbent Candidates and Discarding Any Proxy Materials from the Activist Group Visit www.SafeguardAIM.com for More Information AIM ImmunoTech Inc. (NYSE:AIM) (the "Company") today announced that the Company has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its upcoming 2024 Annual M
Company's SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry OCALA, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced the appointment of W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board ("SAB"). "We are pleased to have an SAB comprised of seasoned individuals with expertise across a wide range of fields and their continued input will provide valuable insight as we continue to adv
OCALA, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced Nancy K. Bryan as the newest member of its Board of Directors. She has also been named to a number of committees. Bryan is an established leader with more than 25 years of experience in the life sciences industry. She has served on executive leadership teams and played key roles in companies' successes, including marketing, sales, business developmen
Year marked by noteworthy operational execution and clinical development progress across pipeline Company reiterates commitment to continued communication and activity with the investment and scientific communities Poised to achieve multiple clinical and regulatory value-driving milestones in 2023 OCALA, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today issued a letter to stockholders highlighting key accomplishments i
OCALA, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced the promotion of Christopher McAleer, Ph.D., from Deputy Scientific Officer to Scientific Officer. "It is a great pleasure to work with such an accomplished scientist as Dr. McAleer. Chris is just as comfortable in the laboratory as he is dealing with Company operational management. Chris will make an excellent Scientific Officer," said David Strayer, MD,
OCALA, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced the appointment of Robert Dickey IV, as its Chief Financial Officer. Effective April 4, 2022, Mr. Dickey will become CFO and Ellen Lintal, who has served as the Company's Chief Financial Officer, will transition to serve as a finance and accounting consultant for AIM. Mr. Dickey has more than 25 years of experience of C-suite financial leadership
Live finance-specific insights
OCALA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends ("Alternate Securities"). The dividend will be issuable to stockholders and Alternate Securities holders of record at the close of business on January 9, 2026 and will be distributed and allocated to DTCC on January 13, 2026. Resulting fractional shares will be rounded down and any resulting fractional shares remaining after the foregoing rounding down will
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the course of the next 18 months provide significant value-driving opportunities, including some trials being partially funded by collaborators AstraZeneca (pancreatic cancer) and Merck (advanced ovarian cancer) Company to host conference call and webcast on Tuesday, April 1st at 8:30 AM ET OCALA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported its financial results for the fourth quarter and full year 2024 and provided a business
– Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving significant momentum with positive clinical trial data, underscoring big pharma collaboration and commercialization opportunities – Company to host conference call and webcast today, November 15th, at 8:30 AM ET OCALA, Fla., Nov. 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") has reported its financial results for the third quarter 2024. As previously announced, the Company will host a conference call and webcast today, November 15, 2024 at 8:30 AM ET (details below). AIM Chief Execu
OCALA, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), announced today that management will host a conference call and webcast to discuss the Company's Q3 2024 operational and financial results on Friday, November 15, 2024 at 8:30 AM ET. The call will be hosted by members of AIM's leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The webcast will be accessible on the Events page of the Invest
– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company to host conference call and webcast today, August 16th at 8:30 AM ET OCALA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported its financial results for the second quarter 2024. As previously announced, the Company will host a conference call and webcast today, Friday, August 16, 2024, at 8:30 AM ET (details below). "We continue to see great potential in Ampligen as we progress across our clinical development programs and look forward to results from our ongoing studies in the near
OCALA, Fla., Aug. 13, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), announced today that management will host a conference call and webcast to discuss the Company's Q2 2024 operational and financial results on Friday, August 16, 2024 at 8:30 AM ET. The call will be hosted by AIM's Chief Executive Officer Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The webcast will be accessible on the Events page of the Investors section of the Company's websi
Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May 16, at 8:30 AM ET OCALA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported its financial results for the first quarter 2024. As previously announced, the Company will host a conference call and webcast today, Thursday, May 16, 2024, at 8:30 AM ET (details below). "AIM is making fundamental progress across our clinical development programs and continues to be encouraged by Ampligen's potential. We recently reported encourag
OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") announced today that management will host a conference call and webcast to discuss the Company's Q1 2024 operational and financial results on Thursday, May 16, 2024, at 8:30 AM ET. The call will be hosted by members of AIM's leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The webcast will be accessible on the Events page of the Investors se
Year marked by growing body of promising data demonstrating Ampligen's potential to address multiple high-value indications Company to host conference call and webcast today, April 2nd at 8:30 AM ET OCALA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported its financial results for the full year 2023 and provided a business update. As previously announced, the Company will host a conference call and webcast today, Tuesday, April 2, 2024, at 8:30 AM ET (details below). "AIM reported positive data across many fronts in 2023 and the first quarter of 2024. We intend to build on this momentum throughout the year, as we
OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") announced today that management will host a conference call and webcast to discuss the Company's Q4/FY2023 operational and financial results on Tuesday, April 2, 2024, at 8:30 AM ET. The call will be hosted by members of AIM's leadership team, Chief Executive Officer Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The webcast will be accessible on the Events page of the Investor
This live feed shows all institutional transactions in real time.
SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)
SC 13G - AIM ImmunoTech Inc. (0000946644) (Subject)
SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)
SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)
SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)
SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)
SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)
SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)
SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)
SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)